New book by Larry Connors Click here Improve your trading - See how
Prostate cancer is a relatively common disease, with over 200,000 new cases diagnosed in the United States each year. The introduction of prostate-specific antigen (PSA) screening has significantly decreased mortality in the last 20 years, such that approximately 30,000 annual deaths are now attributable to this disease. Although PSA is not an ideal diagnostic marker, as it produces both false positives and false negatives, most American males are subjected to PSA screening for prostate cancer. It is therefore important to identify factors which might confound the screening process and create delays in the detection of prostate malignancies. Obesity has been shown to contribute to the sub-optimal efficacy of prostate cancer screening based on PSA levels. Obese men are diagnosed at more advanced stages of the disease relative to normal weight men. They are also at greater risk for recurring elevated PSA levels after surgery and show greater risk of death from prostate cancer relative to normal weight men. One possible explanation for the worsened clinical outcomes in obese men is the observation that obese males generally show lower serum PSA concentrations compared to normal weight men. Dr. Lionel Banez, who has a dual appointment at the Durham VA Medical Center as well as at the Duke University Medical Center, and Dr. Stephen Freedland of the Duke University Medical Center performed a study to examine whether the lower PSA concentrations in obese males might be attributable to an expanded plasma volume, which results in a dilution of their serum PSA levels. In their retrospective study of almost 14,000 men with prostate cancer, they reported that obese men did, in fact, show both increased plasma volume as well as lower PSA concentrations. This suggests that hemodilution may be responsible for the lower PSA concentrations observed in obese men with prostate cancer. These findings were published in the Journal of the American Medical Association (2007; 298(19):2275-2280). Dr. Banez and Dr. Freedland are now planning to conduct a follow-up study which may involve up to 1,000 subjects using the BVA-100. The outcome of this upcoming study may be useful in finding a way to improve the predictive accuracy of cancer screening methods by adjusting for hemodilution. Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com. Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 stephen@daxor.com Diane Meegan Investor Relations 212-330-8512 dmeegan@daxor.com Dr. Sandra Gilbert Clinical Research Coordinator 212-330-8532 sgilbert@daxor.com SOURCE: Daxor Corp. mailto:stephen@daxor.com mailto:dmeegan@daxor.com mailto:sgilbert@daxor.com For full details for DXR click here.
Email Print Archives Feedback Email Article Link
Close X
Most Popular News
UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday December 3 12:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.
The TradingMarkets Directory
Stocks
Options
Forex
E-mini/Futures
How to Trade
Tools
PowerRatings
Blogs
Premium Subscription Services
RELATED SITES
Please call 1-213-955-5858 ext. 1
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice. It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN. The Connors Group, Inc. © Copyright 2009 The Connors Group, Inc. All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy. © 2009 The Connors Group, Inc.
|
